Cytokinetics announced results from a Phase 1 trial last week to determine the safety and tolerability of the company’s lead drug candidate, CK-2017357, an activator of fast skeletal muscle troponin. The drug has considerable market potential for ALS, as most ALS deaths result from respiratory failure due to diminished strength of the skeletal muscles responsible for breathing. Cytokinetics’ drug acts by increasing a muscle fiber’s sensitivity to calcium, leading to a net increase in skeletal muscle force, potentially even in the presence of a weakened motor neuron driving the muscle fiber. Data from the Phase 1 trial indicated the compound was safe and well tolerated and Cytokinetics is now planning to advance its drug into a Phase 2 trial.
Click here to read more.Share this: